Turkcell Iletisim Hizmetleri AS Common Stock (TKC)

Cost of Revenue

₺148.46B

TTM · Period ending: · TRY

TKC logo

TKC Cost of Revenue

Latest reported₺148.46B TRY
TKC TTM Cost of Revenue · TRY (₺1.60B → ₺148.46B)
High-resolution chart · PNG

TKC cost of revenue history

Trailing twelve months (TTM) · TRY. Each value covers four complete reported quarters.

Turkcell Iletisim Hizmetleri AS Common Stock Cost of Revenue — Trailing twelve months (TTM) (TRY)
Period endingCost of Revenue (TRY)
148,464,394,222
131,950,591,222
116,234,086,222
163,842,526,000
150,916,287,000
148,160,914,000
147,214,649,000
136,249,563,000
135,317,178,000
126,621,416,000
115,535,739,000
169,273,055,000
150,861,979,000
132,641,537,000
117,929,921,000
33,451,175,000
30,027,777,000
27,257,276,000
25,229,974,000
23,704,865,000
22,519,950,000
21,333,020,000
20,333,553,000
19,374,529,000
18,410,351,000
17,744,649,000
17,083,480,000
16,366,742,000
15,832,158,000
14,939,531,000
14,145,993,000
13,267,725,000
12,456,111,000
11,848,296,000
11,350,174,000
10,942,291,000
10,381,520,000
9,834,474,000
9,236,607,000
7,840,732,649
7,591,422,186
7,288,428,698
7,208,586,239
8,152,457,800
8,014,171,997
7,873,821,207
7,641,243,567
7,640,030,432
7,458,673,378
7,520,086,399
7,523,876,728
7,117,809,403
6,976,435,736
6,710,109,176
6,489,988,971
6,624,197,256
6,557,226,123
6,453,546,666
6,196,460,931
5,918,119,529
5,545,373,826
5,330,859,720
5,389,489,302
5,142,834,377
5,161,242,989
5,033,790,504
4,790,999,590
5,338,579,665
5,293,364,697
5,186,597,325
5,237,685,333
4,253,372,554
4,018,958,649
3,982,538,954
3,832,575,264
3,653,101,551
3,673,898,392
3,698,685,356
3,645,778,591
3,774,876,327
3,667,407,465
3,411,102,692
3,222,125,165
2,988,410,310
2,846,670,012
2,800,781,552
2,670,612,079
2,675,767,214
2,531,842,468
2,294,654,219
2,152,732,542
1,995,090,573
1,869,761,944
1,842,759,873
1,824,113,044
1,699,742,579
1,648,463,467
1,552,265,421
1,566,348,294
1,933,541,225
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.